440094-14-4Relevant articles and documents
COMPOUNDS
-
Page/Page column 52; 62-63, (2021/12/08)
The invention relates to novel compounds for use as inhibitors of NLRP3 inflammasone production, wherein such compounds are as defined by compounds of formula (I) and wherein the integers R1, R2 and R3 are defined in the description, and where the compounds may be useful as medicaments, for instance for use in the treatment of a disease or disorder that is associated with NLRP3 inflammasome activity.
Synthesis of 2-substituted-3-nitroimidazo[1,2-b]pyridazines as potential biologically active agents
Terme, Thierry,Galtier, Christophe,Maldonado, Jose,Crozet, Michel P.,Gueiffier, Alain,Vanelle, Patrice
, p. 173 - 177 (2007/10/03)
A new heterocyclic reductive alkylating agent, 6-chloro-2-chloromethyl-3-nitroimidazo[1,2-b]pyridazine, was synthesized for the first time. It was shown to react under phase-transfer catalysis conditions with 2-nitropropane anion by an SRN1 mechanism to give excellent yield of isopropylidene derivative formed from a base-promoted nitrous acid elimination of C-alkylation product. Extension of this SRN1 reaction to various nitronate anions led to a new class of 3-nitroimidazo[1,2-b]pyridazine derivatives bearing a trisubstituted double bond at the 2-position.